Review of tumor markers for ovarian cancer

Umbach, G. E.

doi:10.1016/0306-9877(84)90166-x

Cited by 5 publications

(2 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Wbile tbere are no generally available antigens or antibodies to aid the diagnosis or management of this tumour type, in recent years several mouse monoc\otid\ antibodies have been described and developed as potential diagnostic agents and/or therapeutic tools in the monitoring and treatment of ovarian cancer (Bast et al, 1984;Umbach, 1984). One in particular, CA-125, is used extensively in the routine post-surgical monitoring of patients witb ovarian cancer (Sekine et al, 1985) and anotber, HMFG-2, has been used for the treatment and imaging of i.p.…”

Section: Introductionmentioning

confidence: 99%

14C1, an antigen associated with human ovarian cancer, defined using a human IgG monoclonal antibody

Gallagher

Al‐Azzawi

Walsh

et al. 1991

Clinical and Experimental Immunology

View full text Add to dashboard Cite

SUMMARYWe bave selected a buman EBV-transformed cell line from tbe involved lympb nodes of an ovarian cancer patient wbicb secretes an IgG 1 K antibody, able to recognize an antigen present on Ibe surface of ovarian cancer cells. The antigen, termed ' 14C1,' bas previously been shown by immunobistological tecbniques to be present on tbe surface of tbe malignant cells witbin tumour specimens. Western blotting analysis bas sbown Ibat tbe majority of primary ovarian cancer specimens and tbree continuous cell lines derived tberefrom express 14CI; otber tissue types were negative. Preliminary biocbemical cbaracterization bas been carried out, wbicb sbows tbat tbe 14CI antigen bas a molecular weight range of 25-32 kD and an isoelectric point from pf 6-3 to 6S. We believe that the 14C1 antigen is immunologically relevant to ovarian cancer patients and may tberefore represent a novel target for botb active and passive immunotherapy.

show abstract

Section: Introductionmentioning

confidence: 99%

14C1, an antigen associated with human ovarian cancer, defined using a human IgG monoclonal antibody

Gallagher

Al‐Azzawi

Walsh

et al. 1991

Clinical and Experimental Immunology

View full text Add to dashboard Cite

show abstract

“…The first involves the use of a biochemical serum tumour marker, but although in gynaecological practice human chorionic gonadotrophin (Newlands et al 1982) and alphafetoprotein (Sell et al 1976) have proved useful in the management of certain ovarian germ cell tumours, no similar markers exist for epithelial ovarian cancer. Indeed, over 40 potential tumour markers have been described (Umbach 1984) but none has proved outstanding in this disease.…”

Section: Introductionmentioning

confidence: 99%

Practical Applications of a Monoclonal Antibody (NDOG₂) against Placental Alkaline Phosphatase in Ovarian Cancer

Davies

Howe

et al. 1985

J R Soc Med

View full text Add to dashboard Cite

Summary: A monoclonal antibody (NDOG2) against placental alkaline phosphatase (PLAP) in ovarian cancer has been used in three ways by the Bristol University Department of Obstetrics & Gynaecology. First, in an indirect immunoperoxidase technique, NDOG2 demonstrated positive standing in 64% of 56 ovarian carcinomas as well as in 25% of 44 benign tumours. The majority of these positive tumours were serous cystadenocarcinomas or serous cystadenomas and there was considerable variation in the expression of this antigen from tumour to tumour. NDOG2 was also used as the basis of two serum assays and, when labelled with 123-iodine (1231), in radioimmunoscintigraphy (RIS) to monitor patients' response to therapy. The first serum assay measures the enzymic activity of PLAP and the second recognizes the antigenicity of the molecules. Assay 2 proved more useful in that it predicted the course of the disease in 45% of patients followed up, whereas Assay 1 was only of use in 25% of cases. RIS proved to be a useful imaging technique and was at least as sensitive as conventional imaging techniques. The common causes of false-positive and false-negative results are described. IntroductionOvarian cancer is the most commonly occurring gynaecological malignancy in the United Kingdom (OPCS 1983) and, because of its propensity for intra-abdominal metastasis, presents particular problems in assessing a patient's response to therapy. In addition, it is a cancer that

show abstract

Tumormarker in der Diagnostik und Verlaufskontrolle beim Ovarialkarzinom

Elling

Pink

1992

Tumormarker Und Immunszintigraphie in Der Gynäkologischen Onkologie

View full text Add to dashboard Cite

Review of tumor markers for ovarian cancer

Cited by 5 publications

References 29 publications

14C1, an antigen associated with human ovarian cancer, defined using a human IgG monoclonal antibody

14C1, an antigen associated with human ovarian cancer, defined using a human IgG monoclonal antibody

Practical Applications of a Monoclonal Antibody (NDOG₂) against Placental Alkaline Phosphatase in Ovarian Cancer

Tumormarker in der Diagnostik und Verlaufskontrolle beim Ovarialkarzinom

Contact Info

Product

Resources

About

Review of tumor markers for ovarian cancer

Cited by 5 publications

References 29 publications

14C1, an antigen associated with human ovarian cancer, defined using a human IgG monoclonal antibody

14C1, an antigen associated with human ovarian cancer, defined using a human IgG monoclonal antibody

Practical Applications of a Monoclonal Antibody (NDOG2) against Placental Alkaline Phosphatase in Ovarian Cancer

Tumormarker in der Diagnostik und Verlaufskontrolle beim Ovarialkarzinom

Contact Info

Product

Resources

About

Practical Applications of a Monoclonal Antibody (NDOG₂) against Placental Alkaline Phosphatase in Ovarian Cancer